Entera Bio Ltd. SEC filings ENTX
Entera Bio Ltd. has 418 filings in SEC EDGAR's recent list, going back to May 1, 2015. Its latest annual report, Form ARS, was filed on Jun 3, 2026 for the period ended Jun 3, 2026. The latest quarterly report (Form 10-Q) was filed on Aug 7, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 27, 2026 (officer or director change, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B3 | Prospectus | Aug 28, 2026 | — |
| S-3 | Shelf registration | Aug 21, 2026 | — |
| S-8 | Employee stock plan registration | Aug 7, 2026 | — |
| 424B3 | Prospectus | May 15, 2026 | — |
| S-3 | Shelf registration | May 8, 2026 | — |
| 424B3 | Prospectus | Jun 6, 2025 | — |
| S-8 | Employee stock plan registration | May 30, 2025 | — |
| S-3 | Shelf registration | May 30, 2025 | — |
| 424B5 | Prospectus supplement | Jan 10, 2025 | — |
| S-8 | Employee stock plan registration | Aug 9, 2024 | — |
| S-8 | Employee stock plan registration | Mar 8, 2024 | — |
| 424B3 | Prospectus | Feb 15, 2024 | — |
| S-3/A | Filing | Feb 14, 2024 | — |
| S-3 | Shelf registration | Feb 2, 2024 | — |
| S-8 | Employee stock plan registration | Jun 2, 2023 | — |
| 424B5 | Prospectus supplement | Sep 2, 2022 | — |
| 424B3 | Prospectus | Jun 10, 2022 | — |
| 424B3 | Prospectus | Jun 10, 2022 | — |
| S-3 | Shelf registration | May 27, 2022 | — |
| S-3 | Shelf registration | May 27, 2022 | — |
| 424B5 | Prospectus supplement | May 7, 2021 | — |
| F-3 | Shelf registration (foreign issuer) | Jul 13, 2020 | — |
| F-3 | Shelf registration (foreign issuer) | Jun 5, 2020 | — |
| S-8 | Employee stock plan registration | Sep 24, 2018 | — |
| 424B4 | Prospectus | Jun 29, 2018 | — |
| F-1/A | Amendment no. 7 to form f-1 | Jun 27, 2018 | — |
| F-1/A | Amendment no. 6 to form f-1 | Jun 25, 2018 | — |
| F-1/A | Amendment no. 5 to form f-1 | Jun 15, 2018 | — |
| F-1/A | Form f-1/a | May 17, 2018 | — |
| F-1/A | Amendment no. 3 to form f-1 | Jan 11, 2018 | — |
| F-1/A | Amendment no. 2 to form f-1 | Jan 5, 2018 | — |
| F-1/A | Form f-1/a | Nov 20, 2017 | — |
| F-1 | Registration statement (foreign issuer) | Nov 9, 2017 | — |
Showing 33 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ENTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Jerusalem
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1638097
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.